Jeff Yass’s Insight Molecular Diagnostics IMDX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$141K Buy
+39,200
New +$174K ﹤0.01% 12294
2022
Q3
– Sell
-2,645
Closed -$48K – 13851
2022
Q2
$48K Sell
2,645
-765
-22% -$17.4K ﹤0.01% 11994
2022
Q1
$102K Sell
3,410
-1,295
-28% -$41.4K ﹤0.01% 11899
2021
Q4
$204K Buy
4,705
+5
+0.1% +$288 ﹤0.01% 11401
2021
Q3
$335K Buy
4,700
+1,045
+29% +$96.1K ﹤0.01% 10337
2021
Q2
$420K Buy
3,655
+820
+29% +$80.1K ﹤0.01% 10000
2021
Q1
$294K Buy
2,835
+1,790
+171% +$170K ﹤0.01% 10645
2020
Q4
$50K Buy
+1,045
New +$38.3K ﹤0.01% 10752

Other funds holding IMDX

Jeff Yass's IMDX Position: Q3 2026 in Review

Jeff Yass opened a new position in Insight Molecular Diagnostics (IMDX) in Q3 2026: 44,042 shares worth $158K. The stake represents ﹤0.01% of the portfolio and ranks #12181 among its holdings. This is a return to the name: Jeff Yass previously reported a position in IMDX as recently as Q1 2026.

Jeff Yass first reported a position in IMDX in Q1 2017 and has held it in 20 quarters since. The position peaked at $543K in Q4 2025. 44 funds tracked by Wall St. Rank hold IMDX as of Q3 2026.

  • Jeff Yass held 44,042 shares of Insight Molecular Diagnostics worth $158K as of Q3 2026.
  • Insight Molecular Diagnostics was a new Jeff Yass position in Q3 2026.
  • Insight Molecular Diagnostics made up ﹤0.01% of Jeff Yass's portfolio in Q3 2026, its #12181 holding.
  • Jeff Yass first reported a position in Insight Molecular Diagnostics in Q1 2017 and has held it in 20 quarters since.
  • Jeff Yass's Insight Molecular Diagnostics position peaked at $543K in Q4 2025.
  • 44 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q3 2026.

Based on Susquehanna International Group's 13F filing for Q3 2026, filed 16 Nov 2026.